1. Academic Validation
  2. Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin

Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin

  • Sci Rep. 2020 Jan 28;10(1):1326. doi: 10.1038/s41598-020-57843-9.
Alexander Herrmann 1 Manfred Roesner 2 Thomas Werner 3 Stefanie M Hauck 4 Alisha Koch 1 Amelie Bauer 1 Martha Schneider 1 Ruth Brack-Werner 5
Affiliations

Affiliations

  • 1 Institute of Virology, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH, Neuherberg, Germany.
  • 2 mroe-consulting, Eppstein, Germany.
  • 3 Department of Computational Medicine and Bioinformatics & Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • 4 Research Unit Protein Science, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH, Munich, Germany.
  • 5 Institute of Virology, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH, Neuherberg, Germany. brack@helmholtz-muenchen.de.
Abstract

Overcoming the global health threat of HIV Infection requires continuous pipelines of novel drug candidates. We identified the γ-pyrone polyketides Aureothin/Neoaureothin as potent hits by anti-HIV screening of an extensive natural compound collection. Total synthesis of a structurally diverse group of Aureothin-derivatives successfully identified a lead compound (#7) superior to Aureothin that combines strong anti-HIV activity (IC90<45 nM), photostability and improved cell safety. Compound #7 inhibited de novo virus production from integrated proviruses by blocking the accumulation of HIV RNAs that encode the structural components of virions and include viral genomic RNAs. Thus, the mode-of-action displayed by compound #7 is different from those of all current clinical drugs. Proteomic analysis indicated that compound #7 does not affect global protein expression in primary blood cells and may modulate cellular pathways linked to HIV Infection. Compound #7 inhibited multiple HIV genotypes, including HIV-type 1 and 2 and synergistically inhibited HIV in combination with clinical Reverse Transcriptase and integrase inhibitors. We conclude that compound #7 represents a promising new class of HIV inhibitors that will facilitate the identification of new virus-host interactions exploitable for Antiviral attack and holds promise for further drug development.

Figures
Products